236 related articles for article (PubMed ID: 28435472)
1. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
Zheng J; Zhao S; Yu X; Huang S; Liu HY
Theranostics; 2017; 7(5):1373-1388. PubMed ID: 28435472
[TBL] [Abstract][Full Text] [Related]
2. Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model.
Mashreghi M; Zamani P; Karimi M; Mehrabian A; Arabsalmani M; Zarqi J; Moosavian SA; Jaafari MR
Biotechnol Prog; 2021 May; 37(3):e3116. PubMed ID: 33369269
[TBL] [Abstract][Full Text] [Related]
3. Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.
Zhong J; Ding J; Deng L; Xiang Y; Liu D; Zhang Y; Chen X; Yang Q
Drug Des Devel Ther; 2021; 15():3985-3996. PubMed ID: 34584404
[TBL] [Abstract][Full Text] [Related]
4. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
5. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
Wang T; Gantier MP; Xiang D; Bean AG; Bruce M; Zhou SF; Khasraw M; Ward A; Wang L; Wei MQ; AlShamaileh H; Chen L; She X; Lin J; Kong L; Shigdar S; Duan W
Theranostics; 2015; 5(12):1456-72. PubMed ID: 26681989
[TBL] [Abstract][Full Text] [Related]
6. Aptamers as potential therapeutic agents for ovarian cancer.
Henri JL; Macdonald J; Strom M; Duan W; Shigdar S
Biochimie; 2018 Feb; 145():34-44. PubMed ID: 29224849
[TBL] [Abstract][Full Text] [Related]
7. Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors.
Xiang D; Zheng C; Zhou SF; Qiao S; Tran PH; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W
Theranostics; 2015; 5(10):1083-97. PubMed ID: 26199647
[TBL] [Abstract][Full Text] [Related]
8. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
[TBL] [Abstract][Full Text] [Related]
9. Selection and targeting of EpCAM protein by ssDNA aptamer.
Alshaer W; Ababneh N; Hatmal M; Izmirli H; Choukeife M; Shraim A; Sharar N; Abu-Shiekah A; Odeh F; Al Bawab A; Awidi A; Ismail S
PLoS One; 2017; 12(12):e0189558. PubMed ID: 29245156
[TBL] [Abstract][Full Text] [Related]
10. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
11. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging.
Roy K; Kanwar RK; Kanwar JR
Biomaterials; 2015 Dec; 71():84-99. PubMed ID: 26318819
[TBL] [Abstract][Full Text] [Related]
12. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of aptamer-doxorubicin conjugates in an ovarian cancer cell line.
Henri JL; Nakhjavani M; McCoombe S; Shigdar S
Biochimie; 2023 Jan; 204():108-117. PubMed ID: 36155804
[TBL] [Abstract][Full Text] [Related]
14. Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer.
Rehmani H; Li Y; Li T; Padia R; Calbay O; Jin L; Chen H; Huang S
Signal Transduct Target Ther; 2020 Aug; 5(1):140. PubMed ID: 32820156
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
Li YN; Li YY; Wang SX; Ma XY
Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369
[TBL] [Abstract][Full Text] [Related]
16. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture.
Song Y; Zhu Z; An Y; Zhang W; Zhang H; Liu D; Yu C; Duan W; Yang CJ
Anal Chem; 2013 Apr; 85(8):4141-9. PubMed ID: 23480100
[TBL] [Abstract][Full Text] [Related]
17. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.
Lee S; Ahn HJ
Acta Biomater; 2019 Jun; 91():258-269. PubMed ID: 31026519
[TBL] [Abstract][Full Text] [Related]
18. Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells.
Macdonald J; Denoyer D; Henri J; Jamieson A; Burvenich IJG; Pouliot N; Shigdar S
Nucleic Acid Ther; 2020 Apr; 30(2):117-128. PubMed ID: 32027209
[TBL] [Abstract][Full Text] [Related]
19. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
[TBL] [Abstract][Full Text] [Related]
20. EpCAM-Targeting Aptamer Radiotracer for Tumor-Specific PET Imaging.
Li F; Zeng Z; Hamilton D; Zu Y; Li Z
Bioconjug Chem; 2021 Jun; 32(6):1139-1145. PubMed ID: 34014641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
